BiCAPPA
BiCAPPA is the first bivalent antiprion ligand. BiCAPPA can decrease infectious conformational form of prion protein (PrPSc) from scrapie-infected cells, with an EC50 of 0.32 μM[1][2].
Product Specifications
CAS Number
119662-55-4
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Prion Protein
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bicappa.html
Purity
98.35
Solubility
DMSO : 9.52 mg/mL (ultrasonic; adjust pH to 4 with TFA)
Smiles
ClC(C=CC1=C2NCCCN3CCN(CCCNC4=C5C=CC(Cl)=CC5=NC6=C4C=C(OC)C=C6)CC3)=CC1=NC7=C2C=C(OC)C=C7
Molecular Formula
C38H40Cl2N6O2
Molecular Weight
683.67
Precautions
H315, H319, H335
References & Citations
[1]Uliassi E, et, al. 10-Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. Design of Hybrid Molecules for Drug Development. 2017, Pages 259-277.|[2]Bongarzone S, et, al. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J Med Chem. 2010 Nov 25;53 (22) :8197-201.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400260-100 1x 100 µL
IgM Immunoglobulin (IM260), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942587-500 1x 500 µL
Cyclin E (G1/S-Phase Cyclin) (CCNE1/2587), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNUB2246-500 1x 500 µL
Melanoma Antigen Family A, 4 / MAGEA4 (CPTC-MAGEA4-1), 0.2mg/mL
Sign In for Pricing
View Details 
